Coverage
-
April 17, 2023
Merck and generic-drug maker Glenmark are set this week to fight multidistrict litigation claims that they gouged buyers of Merck’s blockbuster cholesterol drug Zetia by forging a pay-for-delay deal in 2010. Law360 breaks down the issues and stakes in this rare trial.
1 other articles on this case.
View all »